01/25/23 8:17 AMOTC : AKBLF fda approvalU.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for AdolescentsALK, a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced that the U.S. Food and Drug Administration approved ODACTRA ® Tablet for Sublingual Use for the treatment of house dust mite- induced allergic rhinitis in persons ages 12 through 17. ODACTRA was first launched for adults, ages...RHEA-AInegative
06/03/21 8:00 AMOTC : AKBLF acquisitionALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and PatientsALK ( ALKB:DC / OMX:ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the diagnosis and treatment of allergies, announced today that it has acquired OTIPRIO ® (ciprofloxacin otic suspension) from Otonomy, Inc.RHEA-AIneutral
